OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
So Yoon Choi, Young Ok Choi, Yon Ho Choe, et al.
Journal of Korean Medical Science (2020) Vol. 35, Iss. 17
Open Access | Times Cited: 14

Showing 14 citing articles:

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109

Present and Future Therapeutic Approaches to Barrier Dysfunction
Marina Fortea, Mercé Albert-Bayo, Mar Abril-Gil, et al.
Frontiers in Nutrition (2021) Vol. 8
Open Access | Times Cited: 27

Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
Akshay Kapoor, Eileen Crowley
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 15

Therapeutic Drug Monitoring of Biologics in Crohn’s Disease
Laurie B. Grossberg, Adam S. Cheifetz, Konstantinos Papamichael
Gastroenterology Clinics of North America (2022) Vol. 51, Iss. 2, pp. 299-317
Closed Access | Times Cited: 10

Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology (2022) Vol. 37, Iss. 8, pp. 1434-1445
Open Access | Times Cited: 9

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
Eun Sil Kim, Ben Kang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 18, pp. 2784-2797
Open Access | Times Cited: 4

Adalimumab in Pediatric Inflammatory Bowel Disease
So Yoon Choi, Ben Kang
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 6

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Ju Young Kim, Yoon Lee, Byung‐Ho Choe, et al.
Gut and Liver (2020) Vol. 15, Iss. 4, pp. 588-598
Open Access | Times Cited: 5

Clinical Significance of histologic healing in IBD: Evidence from randomized controlled trials (RCT) and real world (RW) data
María Manuela Estevinho, Joana Roseira, Pedro Vilela Teixeira, et al.
Digestive and Liver Disease (2024)
Closed Access

Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease
Begoña Rodríguez Azor, Rafael Martín‐Masot, Anita Dayaldasani Khialani, et al.
Anales de Pediatría (English Edition) (2023) Vol. 98, Iss. 3, pp. 165-174
Open Access | Times Cited: 1

La monitorización proactiva de niveles de anti-TNF mejora el seguimiento de los pacientes pediátricos con enfermedad de Crohn
Begoña Rodríguez Azor, Rafael Martín‐Masot, Anita Dayaldasani Khialani, et al.
Anales de Pediatría (2022) Vol. 98, Iss. 3, pp. 165-174
Open Access | Times Cited: 2

Pediatric-onset Inflammatory Bowel Disease: What Are Different from Adult in the Treatment?
Soyoon Choi, Won Moon
Korean Journal of Gastroenterology (2021) Vol. 77, Iss. 5, pp. 220-226
Open Access

Page 1

Scroll to top